Biotech News

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Benitec Biopharma (BNTC)Benitec BiopharmaFDA / regulatory

BNTC (BNTC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bntc.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BNTCBenitec Biopharma2026-10-05 12:00 EST

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

BNTCBenitec Biopharma2026-03-09 11:00 EST

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

ABUSArbutus2026-04-15 11:30 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

ABUSArbutus2026-10-22 11:30 EST

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

RHHBYRoche Holdings AG2026-11-16 22:15 EST

FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

RHHBYRoche Holdings AG2026-11-16 06:00 EST

Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy

PHARPharming Group2026-03-24 06:00 EST

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

PHARPharming Group2026-09-25 14:30 EST

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

BNTXBioNTech2026-08-27 20:30 EST

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

Benitec Biopharma

Genetic Medicine Company Benitec Biopharma develops genetic medicines for neuromuscular and other inherited disorders. Its approach combines gene silencing with gene replacement in a single therapeutic construct. Silence and Replace Platform The company's DNA-directed RNA interference technology is designed to suppress expression of a...

Recent company news

Stock data

Close
8.14 USD
Market cap
363.47M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States